 |
Printer Friendly
Printed from http://www.researchandmarkets.com/reports/992999
Australia In Vitro Diagnostics Investment Opportunities, Analysis and Forecasts to 2015
|
Description: |
Australia In Vitro Diagnostics Investment Opportunities, Analysis and Forecasts to 2015
Summary
This report is an essential source for in-depth information and data relating to Australia In vitro diagnostic dvices market. It also offers detailed and comprehensive coverage of market revenue, distribution and company share information; and the latest news, financial deals and pipeline products information of each of the key sub-segments of the in vitro diagnostics market in Australia
Scope
- The report provides information on the Australian in vitro diagnostics market, broken down into detailed categories and segments such as In Vitro Diagnostics, Clinical Chemistry Test Reagents, Immunochemistry Test Reagents, Blood Test Reagents, Microbiology Test Reagents, Infectious Immunology, Test Reagents, Genetic Test Reagents, Self Testing, and Instruments.
- Total revenues, end users
- Market shares of all the key competitors.
- Key pipeline products that are set to shape the market, broken down by sector.
- Information on the top medical equipment companies in the sector in the country covering business description, strategic analysis.
- Healthcare structure, regulatory environment, approval process, pricing trends and reimbursement.
- Product and brand updates, strategy changes, R&D projects, corporate expansions and contractions and regulatory changes.
- Key mergers and acquisitions, partnerships, private equity investments and IPOs.
- Customer, hospitals and physicians data.
Reasons to buy
- Gain a strong understanding of the in vitro diagnostics devices market in Australia.
- Evaluate and compare the attractiveness of the market in the country.
- Identify growth segments and opportunities in each industry sector within the country.
- Evaluate the pipeline of key products that will change the sector, and identify threats and opportunities before the products are launched in the country.
- Analyze the competitiveness of the market in the country and identify hotspots.
- Develop strategies based on the latest product, brand, expansion and research and development news in the country.
- Do deals with an understanding of how competitors are financed, and the mergers and partnerships that have shaped the market in the country.
- Identify and analyze the strengths and weaknesses of the industry incumbents in the country. |
|
Contents: |
1
1.1 List of Tables
1.2 List of Figures
2 Introduction
2.1 What Is This Report About?
3 Definitions of Markets Covered in This Report
3.1 In Vitro Diagnostics
3.2 Clinical Chemistry
3.3 Genetic Testing
3.4 Haematology
3.5 Histology And Cytology
3.6 Immuno Chemistry
3.7 Infectious Immunology
3.8 Microbiology Culture
4 Healthcare Sector Review
4.1 Healthcare Expenditure
4.2 Healthcare Infrastructure
4.3 Healthcare Policy
5 Regulation System
5.1 Medical Equipment Approval Process
5.2 Advertising
5.3 Labeling and Packaging
5.4 Post-market Surveillance
5.5 Registration Fee
6 Pricing and Reimbursement
7 Distribution Structure
8 In Vitro Diagnostics In Australia
8.1 In Vitro Diagnostics, Australia, Overall Revenue ($ mn), 2000-
8.2 In Vitro Diagnostics, Australia, Company Share (2007-2008)
9 Clinical Chemistry In Australia
9.1 Clinical Chemistry Overall Revenue (2000-2015)
9.2 Clinical Chemistry Distribution Share (2007-2008)
9.3 Clinical Chemistry, Australia, Company Share (2007-2008)
10 Genetic Testing In Australia
10.1 Genetic Testing Overall Revenue (2000-2015)
10.2 Genetic Testing Distribution Share (2007-2008)
10.3 Genetic Testing, Australia, Company Share (2007-2008)
11 Haematology In Australia
11.1 Haematology Overall Revenue (2000-2015)
11.2 Haematology Distribution Share (2007-2008)
11.3 Haematology, Australia, Company Share (2007-2008)
12 Histology And Cytology In Australia
12.1 Histology And Cytology Overall Revenue (2000-2015)
12.2 Histology And Cytology Distribution Share (2007-2008)
12.3 Histology And Cytology, Australia, Company Share (2007-2008)
13 Immuno Chemistry In Australia
13.1 Immuno Chemistry Overall Revenue (2000-2015)
13.2 Immuno Chemistry Distribution Share (2007-2008)
13.3 Immuno Chemistry, Australia, Company Share (2007-2008)
14 Infectious Immunology In Australia
14.1 Infectious Immunology Overall Revenue (2000-2015)
14.2 Infectious Immunology Distribution Share (2007-2008)
14.3 Infectious Immunology, Australia, Company Share (2007-2008)
15 Microbiology Culture In Australia
15.1 Microbiology Culture Overall Revenue (2000-2015)
15.2 Microbiology Culture Distribution Share (2007-2008)
15.3 Microbiology Culture, Australia, Company Share (2007-2008)
16 Overview of Key Companies in India In Vitro Diagnostics Market
16.1 F. Hoffmann-La Roche Ltd.
16.2 Siemens Healthcare
16.3 Sysmex Corporation
16.4 Abbott Laboratories
16.5 Beckman Coulter, Inc.
16.6 Ortho-Clinical Diagnostics Inc.
16.7 OLYMPUS CORPORATION
16.8 Qiagen N.V.
16.9 bioMerieux S.A.
16.10 Bio-Rad Laboratories, Inc.
16.11 Phadia AB
16.12 DiaSorin S.p.A
16.13 Becton, Dickinson and Company
16.14 Gen-Probe Incorporated
16.15 Inverness Medical Innovations, Inc.
16.16 Dade Behring Holdings, Inc.
16.17 Ventana Medical Systems, Inc.
16.18 Vision BioSystems Ltd
16.19 Cellestis Limited
16.20 GeneWorks Pty. Ltd.
16.21 Astral Scientific Pty Ltd
16.22 Enterix Australia Pty Ltd
16.23 Cellabs Pty Ltd
16.24 Diagnostic Technology
16.25 Universal Biosensors, Inc.
16.26 Panbio Limited
17 Financial Deals Landscape
17.1 Partnerships
18 Recent Developments
18.1 Government and Public Interest
19 Appendix
19.1 Global Markets Direct Research Methodology
19.2 Secondary Research
19.3 Primary Research
19.4 Models
19.5 Forecasts
19.6 Expert Panel Validation
19.7 Currency Conversion
19.8 Contact Us
19.9 Disclaimer
Executive Summary
1.1 List of Tables
Table 1: Total Healthcare Expenditure, Australia, 2000 - 2007 27
Table 2: Healthcare Infrastructure in Australia, 2005 30
Table 3: Healthcare Personnel in Australia, 2005 31
Table 4: Hospital Wards by Specialty in Australia, 2003-2007 32
Table 5: Doctors by Specialty in Australia, 2003-2007 33
Table 6: Conformity Assessment of Medical Devices based Device Class, in Australia, 2007 45
Table 7: Fee for Registered Device in Australia, 2007 47
Table 8: Fee for Device Clinical Trial in Australia, 2007 48
Table 9: Evaluation Fee for High and Low Level Registration of Medical Device in Australia, 2007 48
Table 10: Evaluation Fee for Variation Registration of Medical Device in Australia, 2007 49
Table 11: Fee for Registration of Listed Devices in Australia, 2007 49
Table 12: Fee for Registration of Listed Devices for Export Only in Australia, 2007 50
Table 13: Fee for Registration of Included Devices in Australia, 2007 50
Table 14: Fee for Initial Conformity Assessment of Medical Device in Australia, 2007 51
Table 15: Fee for Medical Device Changes Conformity Assessment in Australia, 2007 51
Table 16: Fee for Medical Device Conformity Assessment Surveillance Audit in Australia, 2007 51
Table 17: Fee for Medical Device Conformity Assessment Review Certificate in Australia, 2007 52
Table 18: Fee for Initial Conformity Assessment of Medical Device Components in Australia, 2007 52
Table 19: Fee for Conformity Assessment of Changes in Medical Device Components in Australia, 2007 52
Table 20: Fee for Abridged Conformity Assessment of Medical Device Components in Australia, 2007 53
Table 21: Fee for Inclusion of Medical Device in the Register in Australia, 2007 53
Table 22: Fee for ARTG Inclusion for Medical Device in Australia, 2007 54
Table 23: In Vitro Diagnostics, Australia, Overall Revenue ($ mn), 2000-2015 57
Table 24: In Vitro Diagnostics, Australia, Cross-Category Analysis, 2000-2015 58
Table 25: In Vitro Diagnostics, Australia, Overall Revenue ($ mn), Historic, 2000-2008 60
Table 26: In Vitro Diagnostics, Australia, Overall Revenue ($ mn), Forecast, 2008-2015 62
Table 27: In Vitro Diagnostics, Australia, Company Share by Revenue ($ mn), 2007-2008 63
Table 28: Clinical Chemistry, Australia, Revenue ($ mn) by Segment, Historic, 2000-2008 65
Table 29: Clinical Chemistry, Australia, Revenue ($ mn) by Segment, Forecast, 2008-2015 67
Table 30: Clinical Chemistry Analyzers, Australia, Revenue ($ mn) by Sub-Segment, Historic, 2000-2008 68
Table 31: Clinical Chemistry Analyzers, Australia, Revenue ($ mn) by Sub-Segment, Forecast, 2008-2015 69
Table 32: Urine Analysis, Australia, Revenue ($ mn) by Sub-Segment, Historic, 2000-2008 70
Table 33: Urine Analysis, Australia, Revenue ($ mn) by Sub-Segment, Forecast, 2008-2015 71
Table 34: Clinical Chemistry, Australia, Distribution Share by Revenue ($mn), 2007-2008 72
Table 35: Clinical Chemistry, Australia, Company Share by Revenue ($ mn), 2007-2008 73
Table 36: Genetic Testing, Australia, Revenue ($ mn) by Segment, Historic, 2000-2008 74
Table 37: Genetic Testing, Australia, Revenue ($ mn) by Segment, Forecast, 2008-2015 75
Table 38: Genetic Testing, Australia, Distribution Share by Revenue ($mn), 2007-2008 76
Table 39: Genetic Testing, Australia, Company Share by Revenue ($ mn), 2007-2008 77
Table 40: Haematology, Australia, Revenue ($ mn) by Segment, Historic, 2000-2008 79
Table 41: Haematology, Australia, Revenue ($ mn) by Segment, Forecast, 2008-2015 81
Table 42: Haematology Reagents, Australia, Revenue ($ mn) by Sub-Segment, Historic, 2000-2008 82
Table 43: Haematology Reagents, Australia, Revenue ($ mn) by Sub-Segment, Forecast, 2008-2015 83
Table 44: Immunohaematology, Australia, Revenue ($ mn) by Sub-Segment, Historic, 2000-2008 84
Table 45: Immunohaematology, Australia, Revenue ($ mn) by Sub-Segment, Forecast, 2008-2015 85
Table 46: Haemostasis, Australia, Revenue ($ mn) by Sub-Segment, Historic, 2000-2008 87
Table 47: Haemostasis, Australia, Revenue ($ mn) by Sub-Segment, Forecast, 2008-2015 89
Table 48: Haematology Rapid Tests, Australia, Revenue ($ mn) by Sub-Segment, Historic, 2000-2008 90
Table 49: Haematology Rapid Tests, Australia, Revenue ($ mn) by Sub-Segment, Forecast, 2008-2015 91
Table 50: Haematology Cell Counters, Australia, Revenue ($ mn) by Sub-Segment, Historic, 2000-2008 92
Table 51: Haematology Cell Counters, Australia, Revenue ($ mn) by Sub-Segment, Forecast, 2008-2015 93
Table 52: Haematology, Australia, Distribution Share by Revenue ($mn), 2007-2008 94
Table 53: Haematology, Australia, Company Share by Revenue ($ mn), 2007-2008 95
Table 54: Histology And Cytology, Australia, Revenue ($ mn) by Segment, Historic, 2000-2008 96
Table 55: Histology And Cytology, Australia, Revenue ($ mn) by Segment, Forecast, 2008-2015 97
Table 56: Histology, Australia, Revenue ($ mn) by Sub-Segment, Historic, 2000-2008 98
Table 57: Histology, Australia, Revenue ($ mn) by Sub-Segment, Forecast, 2008-2015 99
Table 58: Histology And Cytology, Australia, Distribution Share by Revenue ($mn), 2007-2008 100
Table 59: Histology And Cytology, Australia, Company Share by Revenue ($ mn), 2007-2008 101
Table 60: Immuno Chemistry, Australia, Revenue ($ mn) by Segment, Historic, 2000-2008 103
Table 61: Immuno Chemistry, Australia, Revenue ($ mn) by Segment, Forecast, 2008-2015 105
Table 62: Disease Specific Immunochemistry, Australia, Revenue ($ mn) by Sub-Segment, Historic, 2000-2008 106
Table 63: Disease Specific Immunochemistry, Australia, Revenue ($ mn) by Sub-Segment, Forecast, 2008-2015 107
Table 64: Drug Related Testing, Australia, Revenue ($ mn) by Sub-Segment, Historic, 2000-2008 108
Table 65: Drug Related Testing, Australia, Revenue ($ mn) by Sub-Segment, Forecast, 2008-2015 109
Table 66: Endocrinology Tests, Australia, Revenue ($ mn) by Sub-Segment, Historic, 2000-2008 110
Table 67: Endocrinology Tests, Australia, Revenue ($ mn) by Sub-Segment, Forecast, 2008-2015 111
Table 68: Immunochemistry Analyzers, Australia, Revenue ($ mn) by Sub-Segment, Historic, 2000-2008 113
Table 69: Immunochemistry Analyzers, Australia, Revenue ($ mn) by Sub-Segment, Forecast, 2008-2015 115
Table 70: Immuno Chemistry, Australia, Distribution Share by Revenue ($mn), 2007-2008 116
Table 71: Immuno Chemistry, Australia, Company Share by Revenue ($ mn), 2007-2008 118
Table 72: Infectious Immunology, Australia, Revenue ($ mn) by Segment, Historic, 2000-2008 120
Table 73: Infectious Immunology, Australia, Revenue ($ mn) by Segment, Forecast, 2008-2015 122
Table 74: Infectious Immunology, Australia, Distribution Share by Revenue ($mn), 2007-2008 123
Table 75: Infectious Immunology, Australia, Company Share by Revenue ($ mn), 2007-2008 125
Table 76: Microbiology Culture, Australia, Revenue ($ mn) by Segment, Historic, 2000-2008 127
Table 77: Microbiology Culture, Australia, Revenue ($ mn) by Segment, Forecast, 2008-2015 129
Table 78: Microbiology Analyzers, Australia, Revenue ($ mn) by Sub-Segment, Historic, 2000-2008 130
Table 79: Microbiology Analyzers, Australia, Revenue ($ mn) by Sub-Segment, Forecast, 2008-2015 131
Table 80: Microbiology Culture, Australia, Distribution Share by Revenue ($mn), 2007-2008 132
Table 81: Microbiology Culture, Australia, Company Share by Revenue ($ mn), 2007-2008 133
Table 82: Sysmex Corporation Pipeline Products by Equipment Type 135
Table 83: Sysmex Corporation Pipeline Products By Development Stage 135
Table 84: Sysmex Corporation Pipeline Products By Therapy Area 135
Table 85: Sysmex Corporation Pipeline Products By News Summary 136
Table 86: Abbott Laboratories Pipeline Products by Equipment Type 137
Table 87: Abbott Laboratories Pipeline Products By Development Stage 137
Table 88: Abbott Laboratories Pipeline Products By Therapy Area 137
Table 89: Beckman Coulter, Inc. Pipeline Products by Equipment Type 138
Table 90: Beckman Coulter, Inc. Pipeline Products By Development Stage 139
Table 91: Beckman Coulter, Inc. Pipeline Products By Therapy Area 140
Table 92: Beckman Coulter, Inc. Pipeline Products By News Summary 140
Table 93: Ortho-Clinical Diagnostics Inc. Pipeline Products by Equipment Type 141
Table 94: Ortho-Clinical Diagnostics Inc. Pipeline Products By Development Stage 142
Table 95: Ortho-Clinical Diagnostics Inc. Pipeline Products By Therapy Area 142
Table 96: Phadia AB Pipeline Products by Equipment Type 145
Table 97: Phadia AB Pipeline Products By Development Stage 145
Table 98: Phadia AB Pipeline Products By Therapy Area 146
Table 99: Phadia AB Pipeline Products By News Summary 146
Table 100: DiaSorin S.p.A Pipeline Products by Equipment Type 147
Table 101: DiaSorin S.p.A Pipeline Products By Development Stage 147
Table 102: DiaSorin S.p.A Pipeline Products By Therapy Area 147
Table 103: Gen-Probe Incorporated Pipeline Products by Equipment Type 149
Table 104: Gen-Probe Incorporated Pipeline Products By Development Stage 150
Table 105: Gen-Probe Incorporated Pipeline Products By Therapy Area 150
Table 106: Gen-Probe Incorporated Pipeline Products By Clinical Trials 150
Table 107: Gen-Probe Incorporated Pipeline Products By News Summary 151
Table 108: Inverness Medical Innovations, Inc. Pipeline Products by Equipment Type 152
Table 109: Inverness Medical Innovations, Inc. Pipeline Products By Development Stage 153
Table 110: Inverness Medical Innovations, Inc. Pipeline Products By Therapy Area 153
Table 111: Inverness Medical Innovations, Inc. Pipeline Products By Clinical Trials 153
Table 112: Inverness Medical Innovations, Inc. Pipeline Products By News Summary 154
Table 113: Diagnostic Technology Pipeline Products by Equipment Type 158
Table 114: Diagnostic Technology Pipeline Products By Development Stage 158
Table 115: Diagnostic Technology Pipeline Products By Therapy Area 158
Table 116: Diagnostic Technology Pipeline Products By Clinical Trials 158
Table 117: Universal Biosensors, Inc. Pipeline Products by Equipment Type 159
Table 118: Universal Biosensors, Inc. Pipeline Products By Development Stage 159
Table 119: Universal Biosensors, Inc. Pipeline Products By Therapy Area 160
Table 120: Panbio Limited Pipeline Products by Equipment Type 161
Table 121: Panbio Limited Pipeline Products By Development Stage 161
Table 122: Panbio Limited Pipeline Products By Therapy Area 162
Table 123: Panbio Limited Pipeline Products By News Summary 162
Table 124: Anteo Diagnostics Enters Into An Agreement With DioSion Diagnostics 163
Table 125: DxS Signs Cross-Licensing Agreement With Epigenomics 164
Table 126: Prodesse Enters Into A licensing Agreement With Abbott Laboratories 165
Table 127: Clinical Genomics Enters Into An Agreement With Quest Diagnostics 166
Table 128: Circadian Technologies Enters Into An Agreement With Healthscope 167
Table 129: USD to Local Currency, Average Exchange Rate 2008 173 |
|
Companies Mentioned |
F. Hoffmann-La Roche Ltd.
Siemens Healthcare
Sysmex Corporation
Abbott Laboratories
Beckman Coulter, Inc.
Ortho-Clinical Diagnostics Inc.
OLYMPUS CORPORATION
Qiagen N.V.
bioMerieux S.A.
Bio-Rad Laboratories, Inc.
Phadia AB
DiaSorin S.p.A
Becton, Dickinson and Company
Gen-Probe Incorporated
Inverness Medical Innovations, Inc.
Dade Behring Holdings, Inc.
Ventana Medical Systems, Inc.
Vision BioSystems Ltd
Cellestis Limited
GeneWorks Pty. Ltd.
Astral Scientific Pty Ltd
Enterix Australia Pty Ltd
Cellabs Pty Ltd
Diagnostic Technology
Universal Biosensors, Inc.
Panbio Limited |
|
Ordering: |
Order Online - visit http://www.researchandmarkets.com/reports/992999
Order by Fax - using the order form below
Order By Post - print the order form below and send to
|
|
Research and Markets,
Guinness Centre,
Taylors Lane,
Dublin 8,
Ireland.
|
|
|
 |
Page 1 of 2
Printed 13/02/2012 01:29:58 |
|
Fax Order Form
To place an order via fax simply print this form, fill in the information below and
fax the completed form to
646-607-1907 (from USA) or +353 1 6849977 (from Rest of World). If you have any questions please email help@researchandmarkets.net
Order information
Please verify that the product information is correct and select the format you require.
|
|
|
|
Product Name: |
Australia In Vitro Diagnostics Investment Opportunities, Analysis and Forecasts to 2015
|
|
Web Address: |
http://www.researchandmarkets.com/reports/992999
|
|
Office Code: |
|
OC8IHINLSNNSS
|
Report formats
Please enter the quantity of the report format you require.
|
|
Format
|
Quantity
|
Price
|
|
Electronic (PDF)
- Single User
|
|
€1,911.00
|
|
Electronic (PDF)
- Site License
|
|
€3,821.00
|
|
Electronic (PDF)
- Enterprisewide
|
|
€5,732.00
|
Contact information
Please enter all the information below in BLOCK CAPITALS.
|
|
|
First Name: |
Last Name: |
|
Email Address: |
|
|
Job Title: |
|
|
Organisation: |
|
|
Address: |
|
|
City: |
|
|
Postal/Zip Code: |
|
|
Country: |
|
|
Phone Number: |
|
|
Fax Number: |
|
|
Please fax this form to:
(646) 607-1907 or (646) 964-6609 (from USA)
+353-1-481-1716 or +353-1-653-1571 (from Rest of World)
|
|
Page 2 of 2
Printed 13/02/2012 01:29:58
|
|
Payment information
Please indicate the payment method you would like to use by selecting the appropriate
box.
|
|
|
|
|
American Express
|
|
|
Diners Club
|
|
|
Master Card
|
|
|
Visa
|
|
|
|
|
|
|
Cardholder's Name: |
|
|
|
|
Cardholder's Signature: |
|
|
|
|
Expiry Date: |
/ |
|
|
|
Card Number: |
|
|
|
|
CVV Security Code: |
|
|
|
|
Issue Date: |
/ (Diners
Club only)
|
|
|
|
|
|
|
Please post the check, accompanied by this form, to:
Research and Markets,
Guinness Centre,
Taylors Lane,
Dublin 8,
Ireland.
|
|
|
|
|
|
|
Please transfer funds to:
|
|
|
Account number: |
83313083 |
|
Sort code: |
98-53-30 |
|
Swift code: |
ULSBIE2D |
|
IBAN number: |
IE78ULSB98533083313083 |
|
Bank Address: |
Ulster Bank,
27-35 Main St,
Blackrock,
Co. Dublin,
Ireland. |
|
|
|
If you have a Marketing Code please enter it below:
|
|
|
Marketing Code: |
|
|
Please note that by ordering from Research and Markets you are agreeing to our Terms and Conditions at http://www.researchandmarkets.com/info/terms.asp
|
|
Please fax this form to:
(646) 607-1907 or (646) 964-6609 (from USA)
+353-1-481-1716 or +353-1-653-1571 (from Rest of World)
|
|
|
|
|
|
